BioGlobal in USDA deal
29 September, 2003 by Graeme O'NeillBrisbane 'green' agbiotech company BioGlobal has signed a cooperative R&D agreement with the US Department of Agriculture to develop its 'killer application' -- a cocktail of volatile floral compounds to lure noctuid moth pests to a lethal rendezvous
Tech tweak boosts Imugene
26 September, 2003 by Melissa TrudingerA change of promoter has given Imugene's (ASX:IMU) pig and poultry vaccine delivery systems a major boost, the company announced today.
Novogen subsidiary aims to float on Nasdaq
26 September, 2003 by Melissa TrudingerAustralian drug developer Novogen's US subsidiary Marshall Edwards has announced plans to float on the Nasdaq exchange, the company said today, with the prospect of raising up to $US13 million before costs associated with the float.
Celentis swims as PPL sinks
26 September, 2003 by Graeme O'NeillThe collapse of Scottish biotech PPL Therapeutics, of 'Dolly' fame, will force the company to sell off its New Zealand 'biopharm' at south Waikato and its 3000 transgenic sheep.
Gradipore hires CEO after six-month search
25 September, 2003 by Melissa TrudingerSydney-based bioseparations specialist Gradipore (ASX:GDP) has named former investment banker Greg Pynt as its new CEO. Pynt, whose previous roles include being joint head of equity capital markets at Deutsche Bank as well as a stint at Intersuisse, replaced US-based Bob Lieb, who quit the CEO post in May.
Select Vaccines signs hep E deal with Genelabs
25 September, 2003 by Melissa TrudingerMelbourne-based Select Vaccines (ASX:SLT) has signed its first agreement, with Singapore diagnostics company Genelabs Diagnostics, to bring the recently formed company's hepatitis E rapid diagnostic test to market.
Peptech confident in J&J royalty dispute
25 September, 2003 by Melissa TrudingerPeptech (ASX:PTD) is confident of coming out on top in its dispute with Centocor and its parent company Johnson & Johnson, the company said today after announcing the initiation of formal arbitration proceedings against the US firms.
New project to tackle sheep genomics
25 September, 2003 by Graeme O'NeillIn a simpler age, before molecular genetics, CSIRO researchers developed SireSine, a contraption containing a large, waterproof wax crayon strategically mounted around a ram's chest, that allowed him to sign off on the backs of obliging ewes.
Biota in US agreement over SARS tests
24 September, 2003 by Graeme O'NeillBiota (ASX:BTA) has formed an agreement with two US government agencies -- the National Institute of Allergy and Infectious Diseases (NIAID) and the US Army Medical Research Institute of Infectious Diseases (USAMRIID) -- to test the company's antiviral compounds for activity against the SARS virus.
Q-Pharm toasts success after first year in operation
24 September, 2003 by Tanya HollisQueensland's first Phase I clinical trials facility, Q-Pharm, has just celebrated its first birthday with almost 20 clinical trials under its belt already.
Solagran claims success in liver disease drug trials
24 September, 2003 by Tanya HollisBotanical biotech Solagran (ASX: SLA) has announced success in preliminary trials of a bioeffective compound for the treatment of liver diseases.
Epitan partners with pSivida in tanning drug project
24 September, 2003 by Tanya HollisA safe tan in a single injection is the aim of a new collaborative agreement between two Australian biotechnology companies.
Peptech gets green light for dog contraceptive
23 September, 2003 by Graeme O'NeillSydney peptide and protein therapeutics developer Peptech Ltd (ASX:PTD ) has announced that its fully owned subsidiary, Peptech Animal Health (PAH) has received approval to market its Suprelorin six-month contraceptive for dogs in Australia.
ATP Innovations signs MoU with CSU, Wagga Wagga
23 September, 2003 by Tanya HollisTechnology business commercialisation centre ATP Innovations has entered an agreement with Charles Sturt University and Wagga Wagga City Council to help put research on the track to market.
Acrux in major deal with Eli Lilly
23 September, 2003 by Tanya HollisMelbourne drug delivery systems developer Acrux has signed a major deal with global pharmaceutical group Eli Lilly and Company to commercialise its veterinary product line.
